MMS Holdings Expert Insights Blog
Experts at MMS share their insights on trending
topics in the pharmaceutical industry.
SENDing Successful Nonclinical Submissions through Validation, Review, and Beyond
The CDISC Standard for the Exchange of Nonclinical Data (SEND) requirements for US Investigation New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics License Applications (BLAs) requirements, designed to improve the ease of nonclinical data review...
Orphan Drug Designations in the EU: Recent Rare Disease Treatment Updates
aTyr Pharma, Inc. was recently granted orphan drug designation by the European Commission (EC) for Efzofitimod for the treatment of sarcoidosis. Sarcoidosis is characterized by the accumulation of immune cells that form granuloma, which typically begins in the lungs,...
MMS Partners with I-ACT to Advance Children’s Clinical Trials
CANTON, Mich. (February 21, 2023) - MMS, a data-focused contract research organization (CRO) - announced its partnership with the Institute for Advanced Clinical Trials (I-ACT) to accelerate the development of life-saving therapeutics including vaccines, medicines,...
A Recap of 2022’s Orphan Drug Approvals
In the US, a rare disease is defined as one that affects less than 200,000 people. While these specific diseases are considered rare, living with a rare disease is not. In the US alone, over 30 million people are living with 7,000 different types of rare diseases.1 A...
What is the FDA’s New Annual Reporting Requirement for INDs?
The FDA recently proposed to replace its current annual reporting requirements for Investigational New Drug (IND) applications with Development Safety Update Reports (DSURs). What Does the FDA’s Proposed Change Mean? Under 21 CFR 312.33, FDA requires Sponsors with an...
Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth
CANTON, Mich. (2/7/2023) – MMS Holdings (MMS) – an award-winning, data-focused contract research organization (CRO) – announces the expansion of its leadership team with the appointment of Chris Schoonmaker as Chief Operating Officer and Ashu Tandon as Chief...
What is FDA’s Project Renewal? The Modernization of Decades Old Oncology Drug Labels
Project Renewal is an initiative established by the FDA to reassess outdated oncology drug products and modernize them. The Oncology Center of Excellence (OCE) recently approved a labeling update for Genentech’s capecitabine tablet, known as Xeloda. In this labeling...
FDA Updates IND Expanded Access Guidance for Industry
New recommendations for IRB review, informed consent and expanded access policies. FDA recently announced the availability of a revised draft Guidance for industry on expanded access (EA) to investigational new drugs (INDs) for treatment use, which consists of...
What is Regulatory Information Management System (RIMS)?
Regulatory Information Management Systems Software (RIMS) are centralized platforms designed to support and streamline Regulatory Affairs teams and operations. RIMS helps in the creation, organization, submission, and archival of regulatory information in regulated...